Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
J Integr Neurosci ; 23(5): 90, 2024 Apr 29.
Article in English | MEDLINE | ID: mdl-38812392

ABSTRACT

The genome of the Nipah virus (NiV) encodes a variety of structural proteins linked to a diverse array of symptoms, including fevers, headaches, somnolence, and respiratory impairment. In instances of heightened severity, it can also invade the central nervous system (CNS), resulting in more pronounced problems. This work investigates the effects of NiV on the blood-brain barrier (BBB), the vital physiological layer responsible for safeguarding the CNS by regulating the passage of chemicals into the brain selectively. To achieve this, the researchers (MMJAO, AM and MNMD) searched a variety of databases for relevant articles on NiV and BBB disruption, looking for evidence of work on inflammation, immune response (cytokines and chemokines), tight junctions (TJs), and basement membranes related to NiV and BBB. Based on these works, it appears that the affinity of NiV for various receptors, including Ephrin-B2 and Ephrin-B3, has seen many NiV infections begin in the respiratory epithelium, resulting in the development of acute respiratory distress syndrome. The virus then gains entry into the circulatory system, offering it the potential to invade brain endothelial cells (ECs). NiV also has the ability to infect the leukocytes and the olfactory pathway, offering it a "Trojan horse" strategy. When NiV causes encephalitis, the CNS generates a strong inflammatory response, which makes the blood vessels more permeable. Chemokines and cytokines all have a substantial influence on BBB disruption, and NiV also has the ability to affect TJs, leading to disturbances in the structural integrity of the BBB. The pathogen's versatility is also shown by its capacity to impact multiple organ systems, despite particular emphasis on the CNS. It is of the utmost importance to comprehend the mechanisms by which NiV impacts the integrity of the BBB, as such comprehension has the potential to inform treatment approaches for NiV and other developing viral diseases. Nevertheless, the complicated pathophysiology and molecular pathways implicated in this phenomenon have offered several difficult challenges to researchers to date, underscoring the need for sustained scientific investigation and collaboration in the ongoing battle against this powerful virus.


Subject(s)
Blood-Brain Barrier , Henipavirus Infections , Nipah Virus , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/virology , Nipah Virus/physiology , Humans , Henipavirus Infections/metabolism , Henipavirus Infections/virology , Henipavirus Infections/physiopathology , Animals , Viral Tropism/physiology
2.
FEBS Lett ; 595(23): 2854-2871, 2021 12.
Article in English | MEDLINE | ID: mdl-34757622

ABSTRACT

SARS-CoV-2 has infected hundreds of millions of people with over four million dead, resulting in one of the worst global pandemics in recent history. Neurological symptoms associated with COVID-19 include anosmia, ageusia, headaches, confusion, delirium, and strokes. These may manifest due to viral entry into the central nervous system (CNS) through the blood-brain barrier (BBB) by means of ill-defined mechanisms. Here, we summarize the abilities of SARS-CoV-2 and other neurotropic RNA viruses, including Zika virus and Nipah virus, to cross the BBB into the CNS, highlighting the role of magnetic resonance imaging (MRI) in assessing presence and severity of brain structural changes in COVID-19 patients. We present new insight into key mutations in SARS-CoV-2 variants B.1.1.7 (P681H) and B.1.617.2 (P681R), which may impact on neuropilin 1 (NRP1) binding and CNS invasion. We postulate that SARS-CoV-2 may infect both peripheral cells capable of crossing the BBB and brain endothelial cells to traverse the BBB and spread into the brain. COVID-19 patients can be followed up with MRI modalities to better understand the long-term effects of COVID-19 on the brain.


Subject(s)
Blood-Brain Barrier , Henipavirus Infections , Nipah Virus , SARS-CoV-2 , Zika Virus Infection , Zika Virus , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/physiopathology , Blood-Brain Barrier/virology , COVID-19/epidemiology , COVID-19/genetics , COVID-19/metabolism , COVID-19/physiopathology , Henipavirus Infections/epidemiology , Henipavirus Infections/genetics , Henipavirus Infections/metabolism , Henipavirus Infections/physiopathology , Humans , Mutation , Nipah Virus/genetics , Nipah Virus/metabolism , SARS-CoV-2/genetics , SARS-CoV-2/metabolism , Zika Virus/genetics , Zika Virus/metabolism , Zika Virus Infection/epidemiology , Zika Virus Infection/genetics , Zika Virus Infection/metabolism , Zika Virus Infection/physiopathology
3.
Curr Mol Pharmacol ; 13(2): 108-125, 2020.
Article in English | MEDLINE | ID: mdl-31657692

ABSTRACT

BACKGROUND: Nipah virus (NiV) and Hendra virus (HeV) of genus Henipavirus are the deadliest zoonotic viruses, which cause severe respiratory ailments and fatal encephalitis in humans and other susceptible animals. The fatality rate for these infections had been alarmingly high with no approved treatment available to date. Viral attachment and fusion with host cell membrane is essential for viral entry and is the most essential event of viral infection. Viral attachment is mediated by interaction of Henipavirus attachment glycoprotein (G) with the host cell receptor: Ephrin B2/B3, while viral fusion and endocytosis are mediated by the combined action of both viral glycoprotein (G) and fusion protein (F). CONCLUSION: This review highlights the mechanism of viral attachment, fusion and also explains the basic mechanism and pathobiology of this infection in humans. The drugs and therapeutics used either experimentally or clinically against NiV and HeV infection have been documented and classified in detail. Some amino acid residues essential for the functionality of G and F proteins were also emphasized. Therapeutic designing to target and block these residues can serve as a promising approach in future drug development against NiV and HeV.


Subject(s)
Antiviral Agents/pharmacology , Drug Design , Hendra Virus/drug effects , Nipah Virus/drug effects , Animals , Hendra Virus/genetics , Henipavirus Infections/physiopathology , Humans , Nipah Virus/genetics , Virus Internalization/drug effects
4.
Aust Vet J ; 92(6): 213-8, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24730376

ABSTRACT

CASE SERIES: Between 2006 and 2012, there were 11 horses diagnosed with Hendra virus (HeV) on 9 independent premises in New South Wales (NSW). We defined a case of HeV as premises where one or more horses were confirmed to be infected with HeV by PCR. All the cases occurred in the north-eastern region of NSW. In 8 of the 9 cases, infection occurred within 2 months over the winter of 2011. With no exception, the affected horses were kept at pasture on properties visited by flying foxes. Of the 11 horses testing positive for HeV, 5 had an association with a fence, with the horses dead or dying on a fence line. In the majority of cases, disease was an acute illness leading to death within 48 h. When signs of disease were observed, neurological signs predominated. There was limited spread to in-contact horses, with only two properties having more than one horse affected. There was significant variation in the sampling strategies undertaken by veterinarians. CONCLUSION: Caution is needed to interpret a negative diagnosis when only swabs have been collected.


Subject(s)
Hendra Virus/isolation & purification , Henipavirus Infections/veterinary , Horse Diseases , Animals , Fatal Outcome , Female , Henipavirus Infections/diagnosis , Henipavirus Infections/epidemiology , Henipavirus Infections/physiopathology , Horse Diseases/diagnosis , Horse Diseases/epidemiology , Horse Diseases/physiopathology , Horse Diseases/virology , Horses , Male , New South Wales/epidemiology , Polymerase Chain Reaction/veterinary , Risk Factors
5.
J Virol ; 86(7): 3736-45, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22278224

ABSTRACT

Proteolytic activation of the fusion protein of the highly pathogenic Nipah virus (NiV F) is a prerequisite for the production of infectious particles and for virus spread via cell-to-cell fusion. Unlike other paramyxoviral fusion proteins, functional NiV F activation requires endocytosis and pH-dependent cleavage at a monobasic cleavage site by endosomal proteases. Using prototype Vero cells, cathepsin L was previously identified to be a cleavage enzyme. Compared to Vero cells, MDCK cells showed substantially higher F cleavage rates in both NiV-infected and NiV F-transfected cells. Surprisingly, this could not be explained either by an increased F endocytosis rate or by elevated cathepsin L activities. On the contrary, MDCK cells did not display any detectable cathepsin L activity. Though we could confirm cathepsin L to be responsible for F activation in Vero cells, inhibitor studies revealed that in MDCK cells, cathepsin B was required for F-protein cleavage and productive replication of pathogenic NiV. Supporting the idea of an efficient F cleavage in early and recycling endosomes of MDCK cells, endocytosed F proteins and cathepsin B colocalized markedly with the endosomal marker proteins early endosomal antigen 1 (EEA-1), Rab4, and Rab11, while NiV F trafficking through late endosomal compartments was not needed for F activation. In summary, this study shows for the first time that endosomal cathepsin B can play a functional role in the activation of highly pathogenic NiV.


Subject(s)
Cathepsin B/metabolism , Endosomes/enzymology , Henipavirus Infections/enzymology , Henipavirus Infections/virology , Nipah Virus/metabolism , Viral Fusion Proteins/metabolism , Animals , Cathepsin B/genetics , Cathepsin L/genetics , Cathepsin L/metabolism , Cell Line , Dogs , Endocytosis , Endosomes/virology , Henipavirus Infections/genetics , Henipavirus Infections/physiopathology , Humans , Mice , Mice, Knockout , Nipah Virus/genetics , Viral Fusion Proteins/genetics
6.
J Virol ; 86(6): 3014-26, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22238299

ABSTRACT

Hendra virus is a highly pathogenic paramyxovirus classified as a biosafety level four agent. The fusion (F) protein of Hendra virus is critical for promoting viral entry and cell-to-cell fusion. To be fusogenically active, Hendra virus F must undergo endocytic recycling and cleavage by the endosomal/lysosomal protease cathepsin L, but the route of Hendra virus F following internalization and the recycling signals involved are poorly understood. We examined the intracellular distribution of Hendra virus F following endocytosis and showed that it is primarily present in Rab5- and Rab4-positive endosomal compartments, suggesting that cathepsin L cleavage occurs in early endosomes. Hendra virus F transmembrane domain (TMD) residues S490 and Y498 were found to be important for correct Hendra virus F recycling, with the hydroxyl group of S490 and the aromatic ring of Y498 important for this process. In addition, changes in association of isolated Hendra virus F TMDs correlated with alterations to Hendra virus F recycling, suggesting that appropriate TMD interactions play an important role in endocytic trafficking.


Subject(s)
Endocytosis , Hendra Virus/metabolism , Henipavirus Infections/physiopathology , Henipavirus Infections/virology , Viral Fusion Proteins/chemistry , Viral Fusion Proteins/metabolism , Amino Acid Motifs , Amino Acid Sequence , Animals , Cell Line , Endosomes/metabolism , Hendra Virus/chemistry , Hendra Virus/genetics , Humans , Molecular Sequence Data , Protein Structure, Tertiary , Protein Transport , Sequence Alignment , Viral Fusion Proteins/genetics
7.
Virus Res ; 162(1-2): 173-83, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21963678

ABSTRACT

The emergence of Hendra and Nipah viruses in the 1990s has been followed by the further emergence of these viruses in the tropical Old World. The history and current knowledge of the disease, the viruses and their epidemiology is reviewed in this article. A historical aside summarizes the role that Dr. Brian W.J. Mahy played at critical junctures in the early stories of these viruses.


Subject(s)
Disease Outbreaks/prevention & control , Genome, Viral , Hendra Virus/genetics , Henipavirus Infections/virology , Nipah Virus/genetics , Reverse Genetics/methods , Swine Diseases/virology , Animals , Australia/epidemiology , Bangladesh/epidemiology , Chiroptera , Communicable Disease Control , DNA, Complementary/genetics , Henipavirus Infections/diagnosis , Henipavirus Infections/epidemiology , Henipavirus Infections/physiopathology , Humans , Malaysia/epidemiology , Plasmids/genetics , Swine , Swine Diseases/diagnosis , Swine Diseases/epidemiology , Swine Diseases/physiopathology , Viral Proteins/chemistry , Viral Proteins/genetics , Virus Replication
9.
Emerg Infect Dis ; 16(3): 507-10, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20202432

ABSTRACT

We infected squirrel monkeys (Saimiri sciureus) with Nipah virus to determine the monkeys' suitability for use as primate models in preclinical testing of preventive and therapeutic treatments. Infection of squirrel monkeys through intravenous injection was followed by high death rates associated with acute neurologic and respiratory illness and viral RNA and antigen production.


Subject(s)
Disease Models, Animal , Henipavirus Infections/physiopathology , Nipah Virus/pathogenicity , Saimiri/virology , Animals , Antibodies, Viral/blood , Antigens, Viral/biosynthesis , Henipavirus Infections/mortality , Henipavirus Infections/virology , Humans , Nipah Virus/genetics , Nipah Virus/immunology , RNA, Viral/biosynthesis
10.
Clin Infect Dis ; 46(7): 977-84, 2008 Apr 01.
Article in English | MEDLINE | ID: mdl-18444812

ABSTRACT

BACKGROUND: In Bangladesh, 4 outbreaks of Nipah virus infection were identified during the period 2001-2004. METHODS: We characterized the clinical features of Nipah virus-infected individuals affected by these outbreaks. We classified patients as having confirmed cases of Nipah virus infection if they had antibodies reactive with Nipah virus antigen. Patients were considered to have probable cases of Nipah virus infection if they had symptoms consistent with Nipah virus infection during the same time and in the same community as patients with confirmed cases. RESULTS: We identified 92 patients with Nipah virus infection, 67 (73%) of whom died. Although all age groups were affected, 2 outbreaks principally affected young persons (median age, 12 years); 62% of the affected persons were male. Fever, altered mental status, headache, cough, respiratory difficulty, vomiting, and convulsions were the most common signs and symptoms; clinical and radiographic features of acute respiratory distress syndrome of Nipah illness were identified during the fourth outbreak. Among those who died, death occurred a median of 6 days (range, 2-36 days) after the onset of illness. Patients who died were more likely than survivors to have a temperature >37.8 degrees C, altered mental status, difficulty breathing, and abnormal plantar reflexes. Among patients with Nipah virus infection who had well-defined exposure to another patient infected with Nipah virus, the median incubation period was 9 days (range, 6-11 days). CONCLUSIONS: Nipah virus infection produced rapidly progressive severe illness affecting the central nervous and respiratory systems. Clinical characteristics of Nipah virus infection in Bangladesh, including a severe respiratory component, appear distinct from clinical characteristics reported during earlier outbreaks in other countries.


Subject(s)
Henipavirus Infections/pathology , Henipavirus Infections/physiopathology , Adolescent , Adult , Antibodies, Viral/blood , Bangladesh/epidemiology , Child , Child, Preschool , Disease Outbreaks , Female , Henipavirus Infections/epidemiology , Henipavirus Infections/mortality , Humans , Male , Middle Aged , Nipah Virus/immunology , Nipah Virus/isolation & purification , Radiography, Thoracic , Respiratory Distress Syndrome/diagnostic imaging , Respiratory Distress Syndrome/pathology , Respiratory Distress Syndrome/physiopathology , Serologic Tests , Time Factors
11.
Ann Neurol ; 62(3): 235-42, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17696217

ABSTRACT

OBJECTIVE: Nipah virus (NiV) is an emerging zoonosis. Central nervous system disease frequently results in high case-fatality. Long-term neurological assessments of survivors are limited. We assessed long-term neurologic and functional outcomes of 22 patients surviving NiV illness in Bangladesh. METHODS: During August 2005 and May 2006, we administered a questionnaire on persistent symptoms and functional difficulties to 22 previously identified NiV infection survivors. We performed neurologic evaluations and brain magnetic resonance imaging (MRI). RESULTS: Twelve (55%) subjects were male; median age was 14.5 years (range 6-50). Seventeen (77%) survived encephalitis, and 5 survived febrile illness. All but 1 subject had disabling fatigue, with a median duration of 5 months (range, 8 days-8 months). Seven encephalitis patients (32% overall), but none with febrile illness had persistent neurologic dysfunction, including static encephalopathy (n = 4), ocular motor palsies (2), cervical dystonia (2), focal weakness (2), and facial paralysis (1). Four cases had delayed-onset neurologic abnormalities months after acute illness. Behavioral abnormalities were reported by caregivers of over 50% of subjects under age 16. MRI abnormalities were present in 15, and included multifocal hyperintensities, cerebral atrophy, and confluent cortical and subcortical signal changes. INTERPRETATION: Although delayed progression to neurologic illness following Nipah fever was not observed, persistent fatigue and functional impairment was frequent. Neurologic sequelae were frequent following Nipah encephalitis. Neurologic dysfunction may persist for years after acute infection, and new neurologic dysfunction may develop after acute illness. Survivors of NiV infection may experience substantial long-term neurologic and functional morbidity.


Subject(s)
Henipavirus Infections/pathology , Henipavirus Infections/physiopathology , Nipah Virus , Adolescent , Adult , Bangladesh , Brain/pathology , Child, Preschool , Disease Progression , Electroencephalography , Encephalitis/pathology , Encephalitis/physiopathology , Enzyme-Linked Immunosorbent Assay , Fatigue/etiology , Female , Follow-Up Studies , Henipavirus Infections/cerebrospinal fluid , Humans , Immunoglobulin G/analysis , Magnetic Resonance Imaging , Male , Middle Aged , Muscle Weakness/etiology , Nervous System Diseases/etiology , Nervous System Diseases/pathology , Nervous System Diseases/physiopathology , Neurologic Examination , Recurrence , Reverse Transcriptase Polymerase Chain Reaction , Surveys and Questionnaires , Survivors
12.
Ann N Y Acad Sci ; 1102: 51-65, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17470911

ABSTRACT

Nipah (NiV) and Hendra (HeV) viruses are members of the newly defined Henipavirus genus of the Paramyxoviridae. Nipah virus (NiV) is an emergent paramyxovirus that causes fatal encephalitis in up to 70% of infected patients, and there is increasing evidence of human-to-human transmission. NiV is designated a priority pathogen in the NIAID Biodefense Research Agenda, and could be a devastating agent of agrobioterrorism if used against the pig farming industry. Endothelial syncytium is a pathognomonic feature of NiV infections, and is mediated by the fusion (F) and attachment (G) envelope glycoproteins. This review summarizes what is known about the pathophysiology of NiV infections, and documents the identification of the NiV receptor. EphrinB2, the NiV and HeV receptor, is expressed on endothelial cells and neurons, consistent with the known cellular tropism for NiV. We discuss how the identification of the henipahvirus receptor sheds light on the pathobiology of NiV infection, and how it will spur the rational development of effective therapeutics. In addition, ephrinB3, a related protein, can serve as an alternative receptor, and we suggest that differential usage of ephrinB2 versus B3 may explain the variant pathogenic profiles observed between NiV and HeV. Thus, identifying the NiV receptors opens the door for a more comprehensive analysis of the envelope-receptor interactions in NiV pathobiology. Finally, we also describe how galectin-1 (an innate immune defense lectin) can interact with specific N-glycans on the Nipah envelope fusion protein, underscoring the potential role that innate immune defense mechanisms may play against emerging pathogens.


Subject(s)
Ephrin-B2/physiology , Ephrin-B3/physiology , Henipavirus Infections/virology , Nipah Virus/pathogenicity , Receptors, Virus/physiology , Viral Envelope Proteins/physiology , Animals , Bioterrorism , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/virology , Disease Outbreaks , Galectin 1/immunology , Henipavirus Infections/epidemiology , Henipavirus Infections/physiopathology , Humans , Nipah Virus/physiology
13.
Expert Rev Anti Infect Ther ; 4(1): 43-55, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16441208

ABSTRACT

Hendra and Nipah virus are closely related emerging viruses comprising the Henipavirus genus of the subfamily Paramyxovirinae and are distinguished by their ability to cause fatal disease in both animal and human hosts. In particular, the high mortality and person-to-person transmission associated with the most recent Nipah virus outbreaks, as well as the very recent re-emergence of Hendra virus, has confirmed the importance and necessity of developing effective therapeutic interventions. Much research conducted on the henipaviruses over the past several years has focused on virus entry, including the attachment of virus to the host cell, the identification of the virus receptor and the membrane fusion process between the viral and host cell membranes. These findings have led to the development of possible vaccine candidates, as well as potential antiviral therapeutics. The common link among all of the possible antiviral agents discussed here, which have also been developed and tested, is that they target very early stages of the infection process. The establishment and validation of suitable animal models of Henipavirus infection and pathogenesis are also discussed as they will be crucial in the assessment of the effectiveness of any treatments for Hendra and Nipah virus infection.


Subject(s)
Antiviral Agents/therapeutic use , Henipavirus Infections/drug therapy , Animals , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antiviral Agents/chemistry , Cats , Cricetinae , Disease Models, Animal , Dogs , Drug Design , Hendra Virus/drug effects , Hendra Virus/immunology , Hendra Virus/pathogenicity , Henipavirus Infections/physiopathology , Henipavirus Infections/prevention & control , Henipavirus Infections/virology , Humans , Mice , Nipah Virus/drug effects , Nipah Virus/immunology , Nipah Virus/pathogenicity , Viral Vaccines/chemistry , Viral Vaccines/therapeutic use
14.
Nihon Rinsho ; 63(12): 2143-53, 2005 Dec.
Article in Japanese | MEDLINE | ID: mdl-16363687

ABSTRACT

Nipah virus (NiV) is a zoonotic paramyxovirus that was first recognized in 1999 as the causative agent of outbreaks of human encephalitis in Malaysia and Singapore, in association with severe respiratory and neurological disease in pigs. Since then, outbreaks of NiV encephalitis have also occurred in Bangladesh during 2001-2004, but without an association to infected swine or other animals. Although NiV infections typically result in acute encephalitis with high mortality, other clinical manifestations, including asymptomatic infection, relapsed encephalitis, and pulmonary disease, have been observed. The article will summarize the virology, epidemiology, clinical features, treatment, and control and prevention of NiV infections in humans.


Subject(s)
Henipavirus Infections , Nipah Virus , Animals , Henipavirus Infections/epidemiology , Henipavirus Infections/physiopathology , Humans , Swine , Zoonoses
15.
Infect Dis Clin North Am ; 19(3): 569-84, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16102649

ABSTRACT

Numerous emerging respiratory tract viruses have been identified as significant causes of acute upper and lower respiratory tract illness in children. Human metapneumovirus is a paramyxovirus discovered in 2001 in the Netherlands, with a seasonal occurrence and spectrum of clinical illness most similar to the closely related respiratory syncytial virus. Several new members of the corona-virus family have been identified, including the truly novel agent of severe acute respiratory syndrome and others that probably have been circulating undetected. Avian influenza strains have caused numerous outbreaks with high mortality, including children, and are potential causes of pandemic influenza. Several zoonotic paramyxoviruses, including Nipah and Hendra viruses, have emerged as occasional causes of sever outbreaks of respiratory tract illness in children and adults.


Subject(s)
Respiratory Tract Infections/virology , Virus Diseases , Child , Coronavirus Infections/epidemiology , Coronavirus Infections/pathology , Coronavirus Infections/physiopathology , Coronavirus Infections/virology , Henipavirus Infections/epidemiology , Henipavirus Infections/pathology , Henipavirus Infections/physiopathology , Henipavirus Infections/virology , Humans , Influenza A Virus, H5N1 Subtype , Influenza, Human/epidemiology , Influenza, Human/pathology , Influenza, Human/physiopathology , Influenza, Human/virology , Metapneumovirus , Paramyxoviridae Infections/epidemiology , Paramyxoviridae Infections/pathology , Paramyxoviridae Infections/physiopathology , Paramyxoviridae Infections/virology , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Syncytial Virus Infections/pathology , Respiratory Syncytial Virus Infections/physiopathology , Respiratory Syncytial Virus Infections/virology , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/pathology , Respiratory Tract Infections/physiopathology , Severe Acute Respiratory Syndrome/epidemiology , Severe Acute Respiratory Syndrome/pathology , Severe Acute Respiratory Syndrome/physiopathology , Severe Acute Respiratory Syndrome/virology , Virus Diseases/epidemiology , Virus Diseases/pathology , Virus Diseases/physiopathology , Virus Diseases/virology
16.
J Virol ; 79(12): 7528-34, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15919907

ABSTRACT

Nipah virus, a newly emerged zoonotic paramyxovirus, infects a number of species. Human infections were linked to direct contact with pigs, specifically with their body fluids. Clinical signs in human cases indicated primarily involvement of the central nervous system, while in pigs the respiratory system was considered the primary virus target, with only rare involvement of the central nervous system. Eleven 5-week-old piglets were infected intranasally, orally, and ocularly with 2.5 x 10(5) PFU of Nipah virus per animal and euthanized between 3 and 8 days postinoculation. Nipah virus caused neurological signs in two out of eleven inoculated pigs. The rest of the pigs remained clinically healthy. Virus was detected in the respiratory system (turbinates, nasopharynx, trachea, bronchus, and lung in titers up to 10(5.3) PFU/g) and in the lymphoreticular system (endothelial cells of blood and lymphatic vessels, submandibular and bronchiolar lymph nodes, tonsil, and spleen with titers up to 10(6) PFU/g). Virus presence was confirmed in the nervous system of both sick and apparently healthy animals (cranial nerves, trigeminal ganglion, brain, and cerebrospinal fluid, with titers up to 10(7.7) PFU/g of tissue). Nipah virus distribution was confirmed by immunohistochemistry. The study presents novel findings indicating that Nipah virus invaded the central nervous system of the porcine host via cranial nerves as well as by crossing the blood-brain barrier after initial virus replication in the upper respiratory tract.


Subject(s)
Central Nervous System Viral Diseases/veterinary , Henipavirus Infections/physiopathology , Nipah Virus/pathogenicity , Swine Diseases/physiopathology , Swine Diseases/virology , Animals , Blood-Brain Barrier/virology , Brain/virology , Central Nervous System/virology , Central Nervous System Viral Diseases/physiopathology , Central Nervous System Viral Diseases/virology , Cerebrospinal Fluid/virology , Cranial Nerves/virology , Female , Guinea Pigs , Henipavirus Infections/virology , Humans , Immunohistochemistry , Swine , Trigeminal Ganglion/virology
18.
J Neurol Neurosurg Psychiatry ; 74(1): 131-3, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12486285

ABSTRACT

The Nipah virus is a newly identified paramyxovirus responsible for an outbreak of fatal encephalitis in Malaysia and Singapore. This paper reports the follow up clinical and magnetic resonance imaging findings in 22 affected subjects. Of 13 patients with encephalitis, one died, one was lost to follow up, and seven recovered. Among the four remaining patients, one had residual sixth nerve palsy, another suffered from severe clinical depression, and a third patient had evidence of retinal artery occlusion. One patient with delayed onset Horner syndrome had a single lesion in the cervical spinal cord. The brain magnetic resonance findings were stable or improved in nine patients over 18 months of follow up. Among a second group of nine asymptomatic seropositive abattoir workers, magnetic resonance examination in seven subjects revealed discrete small lesions in the brain; similar to those detected in encephalitis patients. These findings suggest that in addition to encephalitis, the newly discovered Nipah virus affects the spinal cord and the retina. Late clinical and radiological findings can occur in Nipah virus infections as with other paramyxoviruses.


Subject(s)
Brain/pathology , Encephalitis/diagnosis , Encephalitis/physiopathology , Henipavirus Infections/diagnosis , Henipavirus Infections/physiopathology , Abducens Nerve Diseases/epidemiology , Adult , Aged , Animals , Cerebellar Ataxia/epidemiology , Cerebrospinal Fluid/virology , Comorbidity , Depression/epidemiology , Disease Outbreaks , Disease Progression , Encephalitis/epidemiology , Female , Follow-Up Studies , Henipavirus Infections/epidemiology , Hospital Mortality , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Muscle Weakness/epidemiology , Prospective Studies , Recovery of Function , Retina/pathology , Serologic Tests , Singapore/epidemiology , Spinal Cord/pathology , Swine , Time
SELECTION OF CITATIONS
SEARCH DETAIL
...